Rifat Pamukcu
Director/Board Member presso APREA THERAPEUTICS, INC.
Patrimonio netto: 116 834 $ in data 31/03/2024
Profilo
Rifat Pamukcu is the founder of Cell Pathways, Inc. He currently holds multiple positions including Chairman, President & Chief Executive Officer at Midway Pharmaceuticals, Inc. since 2005, President, Chief Executive Officer & Director at RxMP Therapeutics, Inc. since 2016, Director & Chief Medical Advisor at Atrin Pharmaceuticals LLC, Director at Virion Therapeutics LLC since 2018, Independent Director at Aprea Therapeutics, Inc. since 2022, Director at Syantra, Inc. since 2019, Director at SIRPant Immunotherapeutics, Inc. since 2021, and Managing Partner at Corami LLC since 2016.
He previously worked as a Director at Atrin Pharmaceuticals, Inc. He completed his undergraduate degree at The Johns Hopkins University and his doctorate at the University of Wisconsin.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
APREA THERAPEUTICS, INC.
0.32% | 23/08/2023 | 17 464 ( 0.32% ) | 116 834 $ | 31/03/2024 |
Posizioni attive di Rifat Pamukcu
Società | Posizione | Inizio |
---|---|---|
APREA THERAPEUTICS, INC. | Director/Board Member | 01/05/2022 |
Midway Pharmaceuticals, Inc.
Midway Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Midway Pharmaceuticals, Inc. develops non-antibiotic therapies. It capitalizes on the finding the molecular weight polymers, taken orally but not systemically absorbed, can inhibit the pathogenic behavior of bacteria in the GI tract, enhance gut barrier function and promote gastrointestinal healing. The company was founded by John Alverdy, Eugene Chang and Elaine Petrof in 2005 and is headquartered in Spring House, PA. | Chief Executive Officer | 01/01/2005 |
Atrin Pharmaceuticals LLC
Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | Director/Board Member | - |
RxMP Therapeutics, Inc.
RxMP Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology RxMP Therapeutics, Inc. develops and designs novel hemostatic agents to arrest or prevent excessive bleeding. The company is headquartered in Miami, FL. | Chief Executive Officer | 01/01/2016 |
Virion Therapeutics LLC
Virion Therapeutics LLC BiotechnologyHealth Technology Virion Therapeutics LLC develops chronic viral disease vaccines. It offers ChiVax and ChiVax-gD vaccines. The firm engages in developing immune-based treatments for virally-associated cancers and chronic viral infections. The company was founded by Bernard C. Rudnick, Hildegund C. J. Ertl and Andrew D. Luber in 2018 and is headquartered in Newark, DE. | Director/Board Member | 01/01/2018 |
SIRPant Immunotherapeutics, Inc.
SIRPant Immunotherapeutics, Inc. BiotechnologyHealth Technology SIRPant Immunotherapeutics, Inc. is a clinical-stage immuno-oncology company based in Hummelstown, PA. The company specializes in developing next-generation macrophage-based immunotherapies for the treatment of hematological malignancies and solid tumors. The cell therapy technology employed by SIRPant is based on the reduction of SIRP? expression combined with activation of the patient's own macrophages. This population of SIRP?low activated macrophages is designed to attack the tumor following injection by activating the patient's immune system to produce broad-spectrum anti-tumor activity that utilizes patient T-cells and antibodies targeting cancer neoantigens. The company was founded by Richard F. Fitzgerald, and the CEO is Robert J. Towarnicki. | Director/Board Member | 01/01/2021 |
Corami LLC | Corporate Officer/Principal | 01/01/2016 |
Syantra, Inc.
Syantra, Inc. Miscellaneous Commercial ServicesCommercial Services Syantra, Inc. engages in the development of cancer detection and treatment technology. It offers Syantra DX - Breast Cancer, a blood-based cancer detection assay that utilizes a novel suite of biomarkers and proprietary artificial intelligence-generated algorithms to provide a positive or negative result. The company was founded by Kristina Rinker and Kenneth Fuh and is headquartered in Calgary, Canada. | Director/Board Member | 01/01/2019 |
Precedenti posizioni note di Rifat Pamukcu
Società | Posizione | Fine |
---|---|---|
Cell Pathways, Inc.
Cell Pathways, Inc. Pharmaceuticals: OtherHealth Technology Cell Pathways, Inc. develops and commercializes drugs for the prevention and treatment of cancer | Founder | 01/01/2003 |
░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Formazione di Rifat Pamukcu
The Johns Hopkins University | Undergraduate Degree |
University of Wisconsin | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
APREA THERAPEUTICS, INC. | Health Technology |
Aziende private | 9 |
---|---|
Cell Pathways, Inc.
Cell Pathways, Inc. Pharmaceuticals: OtherHealth Technology Cell Pathways, Inc. develops and commercializes drugs for the prevention and treatment of cancer | Health Technology |
Midway Pharmaceuticals, Inc.
Midway Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Midway Pharmaceuticals, Inc. develops non-antibiotic therapies. It capitalizes on the finding the molecular weight polymers, taken orally but not systemically absorbed, can inhibit the pathogenic behavior of bacteria in the GI tract, enhance gut barrier function and promote gastrointestinal healing. The company was founded by John Alverdy, Eugene Chang and Elaine Petrof in 2005 and is headquartered in Spring House, PA. | Health Technology |
Atrin Pharmaceuticals LLC
Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | Health Technology |
RxMP Therapeutics, Inc.
RxMP Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology RxMP Therapeutics, Inc. develops and designs novel hemostatic agents to arrest or prevent excessive bleeding. The company is headquartered in Miami, FL. | Health Technology |
Virion Therapeutics LLC
Virion Therapeutics LLC BiotechnologyHealth Technology Virion Therapeutics LLC develops chronic viral disease vaccines. It offers ChiVax and ChiVax-gD vaccines. The firm engages in developing immune-based treatments for virally-associated cancers and chronic viral infections. The company was founded by Bernard C. Rudnick, Hildegund C. J. Ertl and Andrew D. Luber in 2018 and is headquartered in Newark, DE. | Health Technology |
Syantra, Inc.
Syantra, Inc. Miscellaneous Commercial ServicesCommercial Services Syantra, Inc. engages in the development of cancer detection and treatment technology. It offers Syantra DX - Breast Cancer, a blood-based cancer detection assay that utilizes a novel suite of biomarkers and proprietary artificial intelligence-generated algorithms to provide a positive or negative result. The company was founded by Kristina Rinker and Kenneth Fuh and is headquartered in Calgary, Canada. | Commercial Services |
SIRPant Immunotherapeutics, Inc.
SIRPant Immunotherapeutics, Inc. BiotechnologyHealth Technology SIRPant Immunotherapeutics, Inc. is a clinical-stage immuno-oncology company based in Hummelstown, PA. The company specializes in developing next-generation macrophage-based immunotherapies for the treatment of hematological malignancies and solid tumors. The cell therapy technology employed by SIRPant is based on the reduction of SIRP? expression combined with activation of the patient's own macrophages. This population of SIRP?low activated macrophages is designed to attack the tumor following injection by activating the patient's immune system to produce broad-spectrum anti-tumor activity that utilizes patient T-cells and antibodies targeting cancer neoantigens. The company was founded by Richard F. Fitzgerald, and the CEO is Robert J. Towarnicki. | Health Technology |
Atrin Pharmaceuticals, Inc.
Atrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 2012, Atrin Pharmaceuticals, Inc. is a DNA Damage Response development company that focuses on a pipeline of products resulting from a series of novel conformationally restricted macrocyclic molecules. Part of Aprea Therapeutics, Inc., the private company is based in Doylestown, PA. Atrin Pharmaceuticals was acquired by Aprea Therapeutics, Inc. on May 16, 2022 for $1.33 million. The company's products have the highest known potency for inhibiting ATR and exhibit ATR selectivity with potential broad therapeutic profile. | Health Technology |
Corami LLC |
- Borsa valori
- Insiders
- Rifat Pamukcu